Key Takeaways
- • Albert Invent raised a $55 million Series B led by TCV at a reported valuation of about $340 million, according to the company's announcement and coverage by Yahoo Finance and Forbes' The Prompt.
- • New investors Delta-v Capital, Socium, HighSage, Coral and Legion joined the round, and existing backers also participated.
- • Albert builds chemistry-native AI tools for chemical discovery and development workflows, rather than general-purpose large language models layered onto lab software.
- • The company's Valence technology is positioned to shorten experimental iteration cycles for materials and specialty chemical teams.
- • The round's valuation will be judged against how quickly Albert converts R&D budgets into recurring software revenue.
Summary
Albert Invent has raised a $55 million Series B led by TCV at a reported valuation of about $340 million, according to the company's announcement and coverage by Yahoo Finance and Forbes' The Prompt. The funding is intended to expand the company's chemistry-native AI platform. New investors in the round include Delta-v Capital, Socium, HighSage, Coral and Legion, while existing backers also returned.
Albert develops AI tools designed around chemical discovery and development workflows, as opposed to generic large language models adapted to lab software. The company has highlighted its Valence technology as part of this stack, which aims to shorten iteration cycles for materials and specialty chemical teams that still rely heavily on experimental trial and error.
The round places Albert among the better-capitalized vertical AI companies selling into industrial R&D. Participation from both specialist and generalist investors, alongside returning shareholders, suggests the round was positioned as a growth step rather than a distressed bridge. The capital is expected to fund product development and go-to-market expansion as chemical and materials companies seek AI systems that understand molecular constraints, not only document search or lab scheduling.
For venture and crossover allocators, the raise reinforces that vertical AI with domain-specific architecture continues to command premium prices where the end market is large and digitally underpenetrated. Chemistry-native models can be harder to build, but switching costs may be higher once they are embedded in discovery pipelines. The reported $340 million valuation will ultimately be judged against how quickly Albert converts R&D budgets into recurring software revenue.
Albert develops AI tools designed around chemical discovery and development workflows, as opposed to generic large language models adapted to lab software. The company has highlighted its Valence technology as part of this stack, which aims to shorten iteration cycles for materials and specialty chemical teams that still rely heavily on experimental trial and error.
The round places Albert among the better-capitalized vertical AI companies selling into industrial R&D. Participation from both specialist and generalist investors, alongside returning shareholders, suggests the round was positioned as a growth step rather than a distressed bridge. The capital is expected to fund product development and go-to-market expansion as chemical and materials companies seek AI systems that understand molecular constraints, not only document search or lab scheduling.
For venture and crossover allocators, the raise reinforces that vertical AI with domain-specific architecture continues to command premium prices where the end market is large and digitally underpenetrated. Chemistry-native models can be harder to build, but switching costs may be higher once they are embedded in discovery pipelines. The reported $340 million valuation will ultimately be judged against how quickly Albert converts R&D budgets into recurring software revenue.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.